RAF413: GLP-1 Weight Loss Drugs - Wegovy, Ozembic, Zepbound and Others
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
RAF413: GLP-1 Weight Loss Drugs - Wegovy, Ozembic, Zepbound and Others
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
On June 4, 2021, the FDA approved Wegovy for the treatment of chronic obesity and overweight individuals. Dr. John Sharretts, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research, said, "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program. FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight."
Read the full post at http://RunningAFEVER.com/413
Photo by Pavel Danilyuk: https://www.pexels.com/photo/woman-in-white-mesh-crop-top-and-pink-bra-7653700/
Pas encore de commentaire